LENZ

LENZ Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website lenz-tx.com
Employees(FY) -
ISIN US52635N1037

Performance

+6.17%

1W

-17.92%

1M

-23.17%

3M

+3.58%

6M

-10.85%

YTD

-20.55%

1Y

Profile

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Advanced Technical Analysis

Technical Analysis of LENZ 2024-05-10

Overview:

In analyzing the technical indicators for LENZ stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible future stock price movement. By examining these key indicators, we aim to offer valuable insights and recommendations for potential inves...

See more ...

Recent News & Updates

2024-05-11 21:03
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-08 04:01
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-05-01 04:01
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024(Globenewswire)
2024-04-03 07:00
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials(Business Wire)
2024-04-02 19:00
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials(Businesswire)
2024-04-02 16:01
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials(Business Wire)
2024-04-02 04:01
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials(Businesswire)
2024-03-21 16:30
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress(Business Wire)
2024-03-20 22:09
11 Stocks that Paid Special Dividends in 2024(Insidermonkey)
2024-03-08 04:00
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics(Businesswire)
2024-02-29 21:48
Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm(Globenewswire)
2024-02-01 22:58
Kuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law Firm(Globenewswire)
2024-01-26 23:07
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates FNCB, PWFL, DOC, GRPH(Globenewswire)
2023-11-15 23:00
What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock(Yahoo Finance)
2023-11-14 18:00
LENZ Therapeutics and Graphite Bio Announce Merger Agreement(Businesswire)
2023-06-22 19:00
Graphite Bio Announces Departure of Chief Financial Officer(Yahoo Finance)
2023-05-14 19:44
Graphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22%(Yahoo Finance)
2023-05-09 22:18
Should You Buy Graphite Bio (GRPH) Ahead of Earnings?(Yahoo Finance)
2023-04-26 02:10
12 Gene Editing Stocks With the Best Long-Term Potential(Yahoo Finance)
2023-03-29 04:20
11 Most Promising Gene Editing Stocks According to Analysts(Yahoo Finance)
2023-03-24 22:12
We're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn Rate(Yahoo Finance)
2023-03-20 04:05
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results(Yahoo Finance)
2023-02-23 04:36
Sickle-cell gene therapy developer stops program, cuts half of staff(Yahoo Finance)
2023-02-22 03:05
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring(Yahoo Finance)
2023-01-09 20:35
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround(Yahoo Finance)
2023-01-06 04:54
Two Covid-era biotech IPOs Spruce and Graphite Bio see stock head in different directions(Yahoo Finance)
2023-01-05 20:07
Graphite Bio Shares Tank After Pausing Sickle Cell Therapy Study(Yahoo Finance)
2023-01-05 04:57
Graphite Bio pauses early-stage blood disease therapy trial(Yahoo Finance)
2023-01-05 03:05
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease(Yahoo Finance)
2022-12-10 21:00
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting(Yahoo Finance)

Page 1 of 3

previousnext